Karger Publishers
Browse
DOCUMENT
Supplementary Material-Podos_Part_2_C3G_biomakers_Supplementary_Figures_Editor_Comments.docx (198.95 kB)
DOCUMENT
Supplementary Material-Podos_Part_2_C3G_biomakers_Supplementary_Materials_Editor_Comments.docx (96.99 kB)
DOCUMENT
Supplementary Material-Podos_Part_2_C3G_biomakers_Supplementary_Tables_Editor_Comments.docx (105.04 kB)
1/0
3 files

Supplementary Material for: Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan

dataset
posted on 2022-11-18, 13:00 authored by Podos S.D., Trachtman H., Appel G.B., Bomback A.S., Dixon B.P., Wetzels J.F.M., Cook H.T., Parikh S.V., Pickering M.C., Tumlin J., Langman C.B., Lightstone L., Sperati C.J., Daina E., Bouman K.P., Rice K., Thanassi J.A., Huang M., Nester C., Remuzzi G.
Introduction: C3 glomerulopathy (C3G) is a rare, progressive kidney disease resulting from dysregulation of the alternative pathway (AP) of complement. Biomarkers at baseline were investigated in patients with C3G who participated in two phase 2 studies with the factor D (FD) inhibitor, danicopan. Methods: Patients with biopsy-confirmed C3G, proteinuria ≥500 mg/day, and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 were enrolled into two studies (NCT03369236 and NCT03459443). Biomarker analysis was performed for patients with C3G confirmed by central pathology laboratory re-evaluation. Complement and clinical biomarkers, biopsy composite score, and activity and chronicity indices were assessed at baseline and analyzed by pairwise Spearman correlation analysis. Results: Twenty-nine patients were included in the analysis (median [interquartile range] age: 24.0 [10.0] years). Systemic complement AP activation was evident by reduced median concentrations of C3 and C5, elevated sC5b-9, and normal C4, relative to reference ranges. C3 showed strong pairwise correlations with C5 and sC5b-9 (r = 0.80 and −0.73, respectively; p < 0.0001). Baseline Ba and FD concentrations were inversely correlated with eGFR (r = −0.83 and −0.87, respectively; p < 0.0001). Urinary concentrations of sC5b-9 were correlated with both plasma sC5b-9 and proteinuria (r = 0.69 and r = 0.83, respectively; p < 0.0001). Biopsy activity indices correlated strongly with biomarkers of systemic AP activation, including C3 (r = −0.76, p < 0.0001), whereas chronicity indices aligned more closely with eGFR (r = −0.57, p = 0.0021). Conclusion: Associations among complement biomarkers, kidney function, and kidney histology may add to the current understanding of C3G and assist with the characterization of patients with this heterogenous disease.

History

Usage metrics

    American Journal of Nephrology

    Categories

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC